Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.

The Editors welcome:

Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology

Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug

The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.

《Expert Opinion On Drug Discovery》是一本由TAYLOR & FRANCIS LTD出版商出版的专业医学期刊，该刊创刊于2006年，刊期Bimonthly，该刊已被国际权威数据库SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 2区，小类学科：药学 2区；在JCR（Journal Citation Reports）分区等级为Q1。该刊发文范围涵盖药学等领域，旨在及时、准确、全面地报道国内外药学工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为7.05，平均审稿速度较慢,6-12周。